bluebird bio Beheer

Beheer criteriumcontroles 2/4

De CEO bluebird bio is Andrew Obenshain, benoemd in Jan2021, heeft een ambtstermijn van 3.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.05M, bestaande uit 22.4% salaris en 77.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.048% van de aandelen van het bedrijf, ter waarde $ 27.95K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.3 jaar en 13.7 jaar.

Belangrijke informatie

Andrew Obenshain

Algemeen directeur

US$3.0m

Totale compensatie

Percentage CEO-salaris	22.4%
Dienstverband CEO	3.8yrs
Eigendom CEO	0.05%
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	13.7yrs

Recente managementupdates

Recent updates

bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors

Nov 15

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Jul 13

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Oct 04

Bluebird bio names interim finance chief

Sep 26

Bluebird bio jumps 17% on FDA approval of new gene therapy

Sep 19

bluebird bio' chief strategy and financial officer to depart

Sep 12

FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia

Aug 17

bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case

Jun 22

bluebird bio: Beaten Down Biotech With Possible Long-Term Potential

May 09

Analyse CEO-vergoeding

Hoe is Andrew Obenshain's beloning veranderd ten opzichte van bluebird bio's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$293m
Jun 30 2024	n/a	n/a	-US$319m
Mar 31 2024	n/a	n/a	-US$301m
Dec 31 2023	US$3m	US$682k	-US$212m
Sep 30 2023	n/a	n/a	-US$63m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$89m
Dec 31 2022	US$2m	US$643k	-US$230m
Sep 30 2022	n/a	n/a	-US$431m
Jun 30 2022	n/a	n/a	-US$507m
Mar 31 2022	n/a	n/a	-US$563m
Dec 31 2021	US$9m	US$486k	-US$563m

Compensatie versus markt: De totale vergoeding ($USD 3.05M ) Andrew } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 650.80K ).

Compensatie versus inkomsten: De vergoeding van Andrew is gestegen terwijl het bedrijf verliesgevend is.

CEO

Andrew Obenshain (50 yo)

3.8yrs

Tenure

US$3,049,181

Compensatie

Mr. Andrew Obenshain has been the Chief Executive Officer and Director of bluebird bio, Inc. since 2021 and serves as its President. He served as President of Severe Genetic Diseases since October 2020 unt...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Andrew Obenshain	President	3.8yrs	US$3.05m	0.048% $ 28.0k
Thomas Klima	Chief Commercial Officer & COO	2.3yrs	US$1.33m	0.087% $ 50.6k
Richard Colvin	Chief Medical Officer	3.7yrs	US$1.34m	0.022% $ 12.9k
Oliver Sterling	CFO & Principal Accounting Officer	less than a year	geen gegevens	geen gegevens
Joseph Vittiglio	Chief Legal & Business Officer and Secretary	1.8yrs	geen gegevens	0.0037% $ 2.2k
Jess Rowlands	Head of Corporate Communications	1.9yrs	geen gegevens	geen gegevens
Andrea Walton	Chief People Officer	2.8yrs	geen gegevens	geen gegevens
Kasra Kasraian	Senior Vice President of Technical Development & Operations	no data	geen gegevens	geen gegevens
Scott Shoemaker	Senior Vice President of Quality	3.8yrs	geen gegevens	geen gegevens
Sarah Alspach	Senior Vice President of External Affairs	1.9yrs	geen gegevens	geen gegevens
Leslie Wilder	VP & Head of Regulatory Science	no data	geen gegevens	geen gegevens
Jessica Whitten	VP & Global Controller	no data	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BLUE wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Andrew Obenshain	President	3.8yrs	US$3.05m	0.048% $ 28.0k
Philip Reilly	Member of Scientific Advisory Board	13.7yrs	geen gegevens	geen gegevens
Philippe Leboulch	Co-Chair of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Stephen Goff	Member of Scientific Advisory Board	13.7yrs	geen gegevens	geen gegevens
Mark Vachon	Independent Chairman	10.3yrs	US$200.91k	0.013% $ 7.5k
Mitchell Finer	Member of Scientific Advisory Board	9.3yrs	US$1.57m	geen gegevens
Malcolm Brenner	Member of Scientific Advisory Board	13.7yrs	geen gegevens	geen gegevens
Christof von Kalle	Member of Scientific Advisory Board	13.7yrs	geen gegevens	geen gegevens
John Agwunobi	Independent Director	7.4yrs	US$160.91k	0.014% $ 7.9k
Nick Leschly	Director	14.7yrs	US$96.41k	0.23% $ 135.6k
R. Humphries	Member of Scientific Advisory Board	13.7yrs	geen gegevens	geen gegevens
Elisabeth Leiderman	Independent Director	3yrs	US$167.91k	0.011% $ 6.6k

13.7yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BLUE zijn ervaren en ervaren (gemiddelde ambtstermijn van 13.7 jaar).

bluebird bio Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

President recently sold US$60k worth of stock

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

Less than half of directors are independent

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

Recent updates

Price target decreased by 24% to US$2.19

bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors

New major risk - Revenue and earnings growth

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio: Scientific Success And Financial Success, And The Gap Between

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

Price target decreased by 13% to US$3.67

Price target decreased by 11% to US$3.78

bluebird bio's Flight Through Financial Fog And Fierce Rivals

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio Is Priced Below IP Value

Price target increased by 8.0% to US$5.00

Bluebird Bio: Innovative Therapies, Monetary Setbacks

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Consensus revenue estimates fall by 13%

Price target decreased by 8.2% to US$6.61

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

Now 31% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

Now 24% undervalued after recent price drop

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

New minor risk - Insider selling

President recently sold US$60k worth of stock

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

Consensus revenue estimates decrease by 26%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Consensus forecasts updated

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Bluebird bio names interim finance chief

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

Bluebird bio jumps 17% on FDA approval of new gene therapy

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

bluebird bio' chief strategy and financial officer to depart

Treasurer recently sold US$78k worth of stock

Consensus forecasts updated

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia

President recently sold US$96k worth of stock

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target increased to US$8.22

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

Chief Regulatory Officer recently sold US$6.7k worth of stock